Can Australia build pharmaceutical resilience before the next supply chain shock?

Australia has pharmaceutical manufacturing capability but remains highly dependent on international supply chains. Image: Getty

Europe’s changing approach to critical medicines offers Australian engineers practical lessons in how to protect supply today while building the manufacturing capability it needs tomorrow.

David Roldao MIEAust is an industrial engineer with more than 20 years of international experience in supply chain, operations and industrial transformation across the pharmaceutical and manufacturing sectors.

During the COVID pandemic, while managing logistics for a health care business supplying a network of hospitals in Portugal, I faced a problem familiar to many supply-chain professionals: inventory had become our insurance against uncertainty.

In March 2021, I was setting up a new logistics distribution centre. With lead times highly uncertain and hospital demand volatile, we were carrying around six months of medical devices and hospital consumables – approximately $17 million in inventory.

After everything we had experienced, the intuitive response might have been to keep that buffer. We did the opposite.

Within months, we reduced inventory by around 60 per cent, from $17 million to almost $8 million – equivalent to approximately six weeks of inventory coverage – while improving delivery performance from around 70 per cent to 93 per cent.

That experience reinforced a lesson that has stayed with me: Resilience is not about having more inventory. It is about knowing where you need inventory, and where you need capability.

Today, managing pharmaceutical supply chains across Europe, North America and Asia, I see that same question being asked at industry and government level.

Two clocks determine access to medicines

For Australian patients, access to medicines has two different clocks. The first is the regulatory and reimbursement clock: how quickly an innovative medicine progresses through approval, health technology assessment and, where applicable, PBS listing. The second is the physical supply-chain clock: once that medicine becomes available, can Australia reliably manufacture, import, store and distribute it?

Faster approval does not solve a supply shortage. Equally, six months of inventory of existing medicines does not give patients earlier access to a new therapy.

Australia already recognises this supply-side risk. Certain PBS medicines are subject to minimum stockholding requirements of four or six months to provide a buffer against supply disruptions.

But stock buys time; it does not create capability.

READ: How engineers can help build smarter, more resilient supply chains

What I am seeing in Europe

The EU’s Critical Medicines Act seeks to strengthen production of critical medicines and their ingredients, diversify supply chains and encourage investment in manufacturing capacity. I can see the same direction in my professional environment.

As pharmaceutical manufacturing demand grows, I am currently involved in qualifying external partners to provide additional capacity and flexibility. When speaking with Portuguese third-party logistics providers, I increasingly hear that pharmaceutical manufacturers, CMOs and CDMOs are asking them not simply to transport products, but to hold raw materials and finished medicines closer to manufacturing operations and markets.

“Horizon Europe could help connect [local] capabilities with European pharmaceutical, engineering and research networks.”
David Roldao MIEAust

This points to an important change: pharmaceutical logistics is becoming part of pharmaceutical infrastructure. Warehousing, temperature control, regulatory compliance, inventory positioning, digital visibility and qualified external capacity are increasingly part of the resilience equation.

For Australia, where distance amplifies lead times and dependence on international supply, that matters.

What should Australia do?

Australia has pharmaceutical manufacturing capability but remains highly dependent on international pharmaceutical supply chains. Trying to manufacture every medicine domestically would be neither realistic nor economically efficient.

Instead, I believe Australia should take three practical steps:

  1. Identify critical dependencies. Which medicines, active pharmaceutical ingredients, technologies and manufacturing capabilities could Australia not afford to lose access to?
  2. Protect critical supply now. For those dependencies, determine the right combination of strategic stock, dual sourcing, geographic diversification and qualified international manufacturing and logistics partners.
  3. Build selected capability for tomorrow. Where the strategic and economic case justifies it, progressively develop domestic manufacturing and technology capability rather than relying indefinitely on inventory.

Inventory creates the time needed to build resilience; it should not become a substitute for building it.

READ: Here’s how reverse engineering could help address global supply chain fragility

Europe as a partner

Europe can help Australia execute the second and third steps.

Portugal provides a useful example. It is a relatively small market, but part of a sophisticated European pharmaceutical manufacturing and logistics ecosystem. The opportunity for Australia is therefore access through countries such as Portugal to a much wider network of European manufacturers, CDMOs, technology providers and specialised logistics partners.

Two recent developments make that opportunity particularly timely.

The Australia–EU Free Trade Agreement, negotiations for which concluded in March 2026, can create stronger conditions for trade and industrial partnerships once it enters into force. For pharmaceuticals, the agreement can provide a platform for more diversified supply, manufacturing partnerships and closer integration between Australian and European pharmaceutical ecosystems.

“The engineering challenge is therefore not to eliminate Australia's dependence on global pharmaceutical supply chains. It is to understand and engineer that dependence.”
David Roldao MIEAust

Australia’s planned association with Horizon Europe from 2027 provides a mechanism for Australian organisations to collaborate with European partners in areas including health, supply-chain security and critical technologies.

I see particular potential in South Australia, where I previously lived and managed industrial operations and supply chains. Having experienced its industrial ecosystem first-hand, I see strong foundations in health and medical research, pharmaceutical and advanced manufacturing, supported by broader engineering and logistics capabilities.

Horizon Europe could help connect those South Australian capabilities with European pharmaceutical, engineering and research networks – turning collaboration into technologies, qualified suppliers and potentially new manufacturing partnerships.

The engineering challenge is therefore not to eliminate Australia’s dependence on global pharmaceutical supply chains. It is to understand and engineer that dependence.

Map what Australia cannot afford to lose. Protect those supplies today, and build selected capabilities tomorrow.

UPCOMING WEBINAR: Medical devices from concept to clinical translation

Exit mobile version